Keyphrases
Left Ventricular Hypertrophy
97%
Inflammation
95%
Metformin
94%
Type 2 Diabetic Patients
54%
Heart Failure
50%
Cardiovascular Disease
45%
Biomarker Signature
45%
Therapeutic Target
45%
Heart Failure with Preserved Ejection Fraction (HFpEF)
45%
Left Ventricular Remodeling
45%
Dapagliflozin
45%
Amino Acid Homeostasis
45%
Diabetic Cardiomyopathy
45%
Metformin Therapy
45%
Pathophysiological Pathways
45%
Patients with Chronic Heart Failure
45%
Metabolic Syndrome
45%
Heart Failure Syndrome
45%
Type 2 Diabetes Mellitus (T2DM)
39%
Global Longitudinal Strain
25%
Pathophysiology
25%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
24%
Branched-chain Amino Acids
22%
Patients with Heart Failure
20%
LV Mass
19%
Placebo
19%
C-reactive Protein
19%
Interleukin-1β
19%
Inflammatory Markers
19%
Metformin Treatment
15%
Therapeutic Action
15%
Amino Acids
15%
Cardiovascular Effects
13%
Tumor Necrosis Factor-α
12%
Neutrophil-to-lymphocyte Ratio
12%
Symptomatic Heart Failure
10%
Validation Cohort
10%
Insulin Resistance
9%
Treatment Strategy
9%
Clinical Outcomes
9%
Targeted Treatment
9%
Unmet Needs
9%
Potential Therapeutic Strategies
9%
Reduced Ejection Fraction
9%
Evidence-based Treatment
9%
Glycemic Control
7%
Glucagon-like
7%
Metformin Use
7%
Clinical Trial Data
7%
Metabolic Properties
7%
Pharmacology, Toxicology and Pharmaceutical Science
Inflammation
100%
Heart Failure
98%
Heart Left Ventricle Hypertrophy
95%
Metformin
94%
Non Insulin Dependent Diabetes Mellitus
76%
Clinical Study
58%
Preclinical Study
45%
Cardiovascular Disease
45%
Metabolic Syndrome X
45%
Diabetic Cardiomyopathy
45%
Biological Marker
45%
Amino Acid
45%
Heart Failure with Preserved Ejection Fraction
45%
Dapagliflozin
45%
Heart Ventricle Remodeling
45%
Pathophysiology
24%
Sodium Glucose Cotransporter 2 Inhibitor
22%
Placebo
21%
Branched Chain Amino Acid
20%
C Reactive Protein
16%
Interleukin 1
16%
Tumor Necrosis Factor
11%
Combination Therapy
10%
Insulin Resistance
9%
Antiinflammatory Activity
6%
Randomized Clinical Trial
6%
Glucagon Like Peptide 1 Receptor Agonist
6%
Cotransporter
5%
Interleukin 6
5%
Interleukin 10
5%
Amino Acid Transporter
5%
Leptin
5%
Protein Tyrosine Kinase
5%
Interleukin 1 Receptor Blocking Agent
5%
Triacylglycerol
5%
High Density Lipoprotein Cholesterol
5%
Comorbidity
5%
Receptor
5%
Receptor Activator of Nuclear Factor Kappa B
5%
Chronic Inflammation
5%
Glutamine
5%
Fatty Acid Binding Protein 4
5%
Cytotoxicity
5%
Medicine and Dentistry
Heart Failure
76%
Clinical Study
58%
Glycon
49%
Diabetic Cardiomyopathy
45%
Left Ventricular Hypertrophy
45%
Cardiovascular Disease
45%
Heart Failure with Preserved Ejection Fraction
45%
Metabolic Syndrome
45%
Biological Marker
45%
Maturity Onset Diabetes of the Young
31%
Cardiovascular System
21%
Pathophysiology
18%
Sodium Glucose Cotransporter 2 Inhibitor
10%
Insulin Resistance
9%
Patient with Type 2 Diabetes
9%
Ejection Fraction
9%
Glucagon-Like Peptide-1 Agonist
6%
Randomized Clinical Trial
6%
Glycemic Control
6%
Antiinflammatory Activity
6%
Cardiovascular Effect
6%
Natural Killer Cell Mediated Cytotoxicity
5%
Receptor Tyrosine Kinase
5%
Upregulation
5%
Lipid Metabolism
5%
Fatty Acid Binding Protein 4
5%
Triacylglycerol
5%
Receptor Activator of Nuclear Factor Kappa B
5%
Leptin
5%
Proto Oncogene
5%
Interleukin 1 Receptor Blocking Agent
5%
High Density Lipoprotein Cholesterol
5%
Immune Response
5%
Chronic Inflammation
5%
